Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure.
about
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.Combined assessment of myocardial damage and electrical disturbance in chronic heart failureHigh sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional study.Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population.Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general populationBiochemical markers of myocyte injury in heart failurePerioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgeryThe serum heart-type fatty acid-binding protein (HFABP) levels can be used to detect the presence of acute kidney injury on admission in patients admitted to the non-surgical intensive care unit.From omics to drug metabolism and high content screen of natural product in zebrafish: a new model for discovery of neuroactive compound.Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study.Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage.Biomarkers for heart failure.Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study.Vitamin D levels and their relationship with cardiac biomarkers in chronic hemodialysis patients.Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6.New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.Lipid chaperones and metabolic inflammation.Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.ST Segment Elevation with Normal Coronaries.Serum myeloperoxidase level is associated with heart-type fatty acid-binding protein but not troponin T in patients with chronic heart failure.Detectable troponin levels predict poor prognosis in patients with left ventricular dysfunction undergoing internal defibrillator implantation.Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit.High peripheral levels of h-FABP are associated with poor prognosis in end-stage heart failure patients with mechanical circulatory support.Cord Blood Biomarkers of Cardiac Dysfunction and Damage in Term Growth-Restricted Fetuses Classified by Severity Criteria.Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure.Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure.Leakage of cardiac troponin I in aortic valve stenosis.
P2860
Q33649348-9C4D6C97-B19B-4578-A3AD-D7AF5CC4F9E3Q33721205-CC5442C2-FED5-4350-B6CE-E432DF3389AAQ33951088-D879D67B-8D52-4046-BE35-1B859F877B52Q34103605-0C75DD1E-5A16-431B-85D7-EB9120C012A6Q35042217-7459F356-BAD7-4790-BEA9-4366E1752802Q35054010-6A394BEB-918C-4515-B4CC-9064B67F8D87Q35887596-74EAD745-3666-4294-AB39-04522083000AQ36016656-F2B7DBFD-D032-452A-A149-ABF2C0F95958Q36123371-775E00D0-5047-4F5D-B705-D9CC5750E0ACQ36167799-46A9F6DC-9358-48D4-BA83-1C4EA47C3A60Q36326775-1599C4E1-45A9-4DB3-806B-6E4C6715795AQ36442078-EA342A61-E8B1-4D0C-8E1A-1834CB9DA4BFQ36684774-CEE0B186-0DEB-4101-A2D4-69C113A29448Q37055493-4DB9B102-B687-4343-8241-97DE32553A73Q37078101-C1F6BF95-750A-4087-A753-8D76B21FFA3BQ37378495-D1AD8357-8F8E-4773-A545-1369834843CBQ38100987-7ED5FD49-B0C1-4659-8385-C4E896318D2EQ38908903-58AB0DE9-0FBE-42F7-9D57-4DDCFD08E0EBQ39484186-81C7DDDE-84D6-42C3-9938-1D781F1A6EE7Q42144941-9887C840-200E-42F8-B321-E6A0B960AFD6Q42756722-C304637E-2E12-4E7E-B9AB-15233274D32EQ43776255-C5ACB2EF-FFE7-4182-B48B-E5A0D82B82B8Q44484688-F0E775B4-CEB4-4102-9E69-F2CE949BC560Q45907477-94B79230-B661-47F4-BCEE-32E0965B44B6Q47347006-942B97DA-C9E6-4344-8638-607C3626DC22Q48030178-F89D3A39-558D-4609-B66B-7987D0F5ED8FQ48582698-B7509EEE-0EC1-401D-AF4F-890125A13B08Q53660327-0B5C05E8-6A21-4C48-8BE9-1E8D3BAC90C7
P2860
Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Use of cytosolic and myofibril ...... ts with chronic heart failure.
@en
Use of cytosolic and myofibril ...... ts with chronic heart failure.
@nl
type
label
Use of cytosolic and myofibril ...... ts with chronic heart failure.
@en
Use of cytosolic and myofibril ...... ts with chronic heart failure.
@nl
prefLabel
Use of cytosolic and myofibril ...... ts with chronic heart failure.
@en
Use of cytosolic and myofibril ...... ts with chronic heart failure.
@nl
P2093
P1476
Use of cytosolic and myofibril ...... ts with chronic heart failure.
@en
P2093
Koichi Setsuta
Masato Arao
Takeshi Ogawa
Teruo Takano
Yoshihiko Seino
Yoshiko Miyatake
P304
P356
10.1016/S0002-9343(02)01394-3
P407
P577
2002-12-01T00:00:00Z